Effects of Advanced Hybrid Closed-loop System on Glycemic Control and Psychosocial Outcomes in Pediatric Patients With Type 1 Diabetes
Prospective, non-randomized, single-arm clinical trial to investigate the effects of advanced hybrid close-loop (AHCL) system insulin pump in pediatric patients with type 1 diabetes
• The subject is age 7-19
• The subject with one or more of the below
‣ serum c-peptide ≤ 0.6 ng/mL at diagnosis
⁃ positive glutamic acid decarboxylase (GAD) antibody
⁃ positive islet cell antibody
⁃ positive anti-Insulin antibody
⁃ positive anti-islet Antigen-2 (IA-2) antibody
• The subject was diagnosed with type 1 diabetes ≥ 1 year
• The subject has been continuously treated at least for 8 weeks at the start of the study, by one of the existing insulin treatment methods \[insulin multi-injection (MDII), general insulin pump (CSII), sensor-linked insulin pump (SAP), or 770G insulin pump (HCL system)\]
• The subject has been applied with real-time continuous glucose monitoring at least for 8 weeks at the start of the study